DNAm scores for serum GDF15 and NT-proBNP levels associate with

2 a range of traits affecting the body and brain

- Danni A. Gadd¹, Hannah M. Smith¹, Donncha Mullin^{2,3}, Ola Chybowska¹, Robert F. Hillary¹, Dorien
- 4 M Kimenai⁴, Elena Bernabeu¹, Yipeng Cheng¹, Chloe Fawns-Ritchie^{1,5}, Archie Campbell¹, Danielle
- 5 Page⁶, Adele Taylor⁶, Janie Corley⁶, Maria Del C. Valdés-Hernández^{6,7,8}, Susana Muñoz
- 6 Maniega^{6,7,8}, Mark E. Bastin^{6,7,8}, Joanna M. Wardlaw^{6,7,8,9}, Rosie M. Walker^{8,10}, Kathryn L. Evans¹,
- Andrew M. McIntosh², Caroline Hayward^{1,13}, Tom Russ^{2,3}, Sarah E. Harris⁶, Paul Welsh¹⁴, Naveed
- 8 Sattar¹⁴, Simon R. Cox⁶, Daniel L. McCartney¹, Riccardo E. Marioni^{1,†}
- ¹ Centre for Genomic and Experimental Medicine, Institute of Genetics and Cancer, University of
- 10 Edinburgh, Edinburgh, UK
- ² Division of Psychiatry, University of Edinburgh, Royal Edinburgh Hospital, Edinburgh, UK
- ³ Alzheimer Scotland Dementia Research Centre, University of Edinburgh, UK
- ⁴ BHF Centre for Cardiovascular Science, University of Edinburgh, UK
- ⁵ Division of Psychology, University of Dundee, Dundee, Scotland, UK
- ⁶ Lothian Birth Cohorts, Department of Psychology, University of Edinburgh, UK
- ⁷ Scottish Imaging Network, A Platform for Scientific Excellence (SINAPSE) Collaboration,
- 17 Edinburgh, UK
- ⁸ Centre for Clinical Brain Sciences, Edinburgh Imaging and UK Dementia Research Institute,
- 19 University of Edinburgh, UK
- ⁹ Neurovascular Imaging Research Core, UCLA, Los Angeles, CA
- 21 ¹⁰ School of Psychology, University of Exeter, Perry Road, Exeter, UK
- 22 ¹¹ British Heart Foundation Data Science Centre, Health Data Research UK, London, UK
- 23 ¹² Health Data Research UK, London, UK
- 24 ¹³ Medical Research Council Human Genetics Unit, Institute of Genetics and Cancer, University of
- 25 Edinburgh, Edinburgh, UK

28

30

- ¹⁴ School of Cardiovascular and Metabolic Health, BHF Glasgow Cardiovascular Research Centre,
- 27 University of Glasgow, 126 University Place, Glasgow, UK
- 29 [†] Corresponding author: Riccardo Marioni, riccardo.marioni@ed.ac.uk

Abstract

32

53

54

33 Background: Plasma growth differentiation factor 15 (GDF15) and N□terminal pro□B□type natriuretic peptide (NT proBNP) are cardiovascular biomarkers that associate with a range of 34 diseases. Epigenetic scores (EpiScores) for GDF15 and NT-proBNP may provide new routes for risk 35 36 stratification. 37 **Results:** In the Generation Scotland cohort ($N \ge 16,963$), GDF15 levels were associated with incident dementia, ischaemic stroke and type 2 diabetes, whereas NT-proBNP levels were associated 38 39 with incident ischaemic heart disease, ischaemic stroke and type 2 diabetes (all $P_{FDR} < 0.05$). Bayesian Epigenome-wide association studies (EWAS) identified 12 and 4 DNA methylation 40 41 (DNAm) CpG sites associated (Posterior Inclusion Probability [PIP] > 95%) with levels of GDF15 and NT-proBNP, respectively. EpiScores for GDF15 and NT-proBNP that were trained in a subset of 42 43 the population. The GDF15 EpiScore replicated protein associations with incident dementia, type 2 44 diabetes and ischaemic stroke in the Generation Scotland test set (Hazard Ratios (HR) range 1.36 -45 1.41, P_{FDR} <0.03). The EpiScore for NT-proBNP replicated the protein association with type 2 diabetes, but failed to replicate an association with ischaemic stroke. EpiScores explained 46 comparable variance in protein levels across both the Generation Scotland test set and the external 47 LBC1936 test cohort (R² range of 5.7-12.2%). In LBC1936, both EpiScores were associated with 48 indicators of poorer brain health. Neither EpiScore was associated with incident dementia in the 49 LBC1936 population. 50 Conclusions: EpiScores for serum levels of GDF15 and Nt-proBNP associate with body and brain 51 52 health traits. These EpiScores are provided as potential tools for disease risk stratification.

Keywords: GDF15, NT-proBNP, epigenetic, DNA methylation, dementia, diabetes,

55 cardiovascular, stroke, risk stratification, brain

Background

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

Delaying or preventing the onset of chronic diseases is a major challenge. Traditional risk factor models provide a foundation to achieve this (1,2), but can be augmented by molecular-level data. Plasma growth differentiation factor 15 (GDF15) and N□terminal pro□B□type natriuretic peptide (NT proBNP) are biomarker candidates that have yielded promising results as indicators of a range of morbidities. GDF15 is associated with low-grade inflammation and age-related immunosuppression (3). Higher levels of GDF15 have been found, through Mendelian randomisation, to causally associate with increased risk of cardiometabolic stroke, atrial fibrillation, coronary artery disease and myocardial infarction (4). Two recent proteome-wide studies that assessed 1,301 (5) and 1,468 (6) proteins identified GDF15 as the top marker of multimorbidity. NTproBNP is a metabolite of pro B-type natriuretic peptide (BNP), which is a natriuretic and diuretic hormone released by heart muscle in response to wall stretch (7). An inverse relationship between the levels of NT-proBNP in blood and incident diabetes has been reported (8), whereas lower levels of NT-proBNP have been associated with more favourable cardiovascular outcomes in randomised control trials (9-11). Elevated levels of GDF15 and NT-proBNP in individuals diagnosed with COVID-19 have been linked to more severe outcomes (12,13). Both protein markers have also been found to associate with vascular brain injury, poorer neurocognitive performance and incident dementias (14,15). DNAm-based epigenetic scores (EpiScores) for blood proteins have been found to serve as markers of incident diseases (16) and augment clinically-used risk factors for risk stratification (17,18). DNAm reflects the body's chronic response to low-grade inflammation, environmental and biological exposures (19-21). A study that directly compared an EpiScore for C-Reactive protein (CRP) to measured CRP found that the EpiScore had greater test-retest reliability over time point measures (22). This suggests that EpiScores may be more stable indictors than measured proteins in some instances. An EpiScore for GDF15 levels based on changes to DNAm at CpG sites across the

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

genome is one of seven protein EpiScores that contribute to GrimAge, a leading epigenetic predictor of biological age acceleration, healthspan and lifespan (23,24). However, the performance of protein EpiScores against within-sample protein measurements in relation to incident diseases has not been comprehensively investigated. Additionally, EpiScores have typically been trained in samples of restricted size, with training sets typically ranging from 775 to 2,356 individuals (25) (23). Here, we assess the viability of EpiScores for serum GDF15 and NT-proBNP as markers of disease outcomes and brain health (Fig. 1). Using GDF15 and NT-proBNP measures available in Generation Scotland (N \geq 16,963), we first profile associations between GDF15 and NT-proBNP and four incident diseases (type 2 diabetes, ischaemic heart disease, ischaemic stroke and dementia), in addition to COVID-19 outcome severity. These diseases were chosen for the study as they have been linked to GDF15 and NT-proBNP and were available through electronic health linkage. We next map the epigenetic architectures of the two proteins, before training and testing protein EpiScores for them in subsets of Generation Scotland. In the test set, direct biomarker comparisons between measured proteins and the EpiScore equivalents are performed in relation to the four incident diseases assessed in the full Generation Scotland sample initially. EpiScores are then retrained in the full sample available and tested externally in the Lothian Birth Cohort 1936 (LBC1936), where associations with brain health traits are also profiled cross-sectionally and longitudinally.




Figure 1. Study design for this assessment of GDF15 and NT-proBNP EpiScores as biomarkers. Disease associations and epigenome-wide association studies (EWAS) for each protein were first characterised in the full Generation Scotland sample. EpiScores for each protein were initially trained and tested in subsets of the population. This allowed EpiScores to be compared with measured proteins in associations with the four incident diseases profiled in the test set. EpiScores were then retrained on the full sample and tested externally in the LBC1936 Wave 4 population, which had measures of both proteins and DNAm available. EpiScores were projected into the larger LBC1936 Wave 1 population (that has DNAm but no protein measures) and profiled in associations with brain health traits, cross-sectionally and longitudinally. Consent for dementia linkage was available from Wave 2 of the LBC1936; therefore, we also tested whether EpiScores were associated with time-to-dementia. EpiScores were modelled with polygenic risk scores (PRS) for the proteins. CpG: cytosine-phosphate-guanine. IHD: ischaemic heart disease.

Results

Sample populations

There were 18,413 Generation Scotland participants (59% female) that had DNAm measurements, with a mean age of 48 years (SD 15), a minimum age of 17 years and maximum age of 98 years (Supplementary Table 1) (26,27). Of these, 17,489 had GDF15 measurements and 16,963 had NT-proBNP measurements. Subsets of this sample that were unrelated to one another were used to initially train and test EpiScores for GDF15 (N_{train} = 8,207, N_{test} = 2,954) and NT-proBNP (N_{train} = 8,002, N_{test} = 2,808) (Supplementary Table 1). Measurements of serum GDF15 and NT-proBNP levels were available at Wave 4 (mean age 79 years, with 0.6 SD) of the LBC1936 study. These samples were used as external test sets for EpiScores trained on the full Generation Scotland sample. Of 507 individuals at Wave 4, 322 had GDF15 measures (48% female) and 500 had NT-proBNP measures (49% female). LBC1936 has successive Waves of measurements (Waves 1-5, collected at mean ages of 70, 73, 76, 79 and 82 years old, with SD < 1 at each Wave) (28,29). EpiScores were projected into Wave 1 (895 individuals with DNAm, but no protein measures) and evaluated in relation to cross-sectional and longitudinal brain health traits. As consent to dementia linkage was available from Wave 2, associations between EpiScores and time-to-dementia were also tested in LBC1936.

GDF15 and NT-proBNP disease associations

Six associations (**Fig. 2**) were identified in Cox proportional hazards (PH) mixed effects models between protein levels and incident diseases in Generation Scotland ($N \ge 16,963$). These associations had False Discovery Rate (FDR) P < 0.05 in basic (age and sex adjusted) models and P < 0.05 in fully-adjusted models (that further adjusted for smoking, alcohol intake, body mass index (BMI), social deprivation and years of education) (**Supplementary Table 2**). Counts for cases, controls and mean time-to-onset for cases are provided in **Supplementary Table 2**. In basic logistic regression models, GDF15 was associated with subsequent hospitalisation due to COVID-19 (odds ratio (OR)

per SD = 2.0, 95% confidence interval (CI) = [1.2, 3.4], FDR P = 0.037), as opposed to having COVID-19 without hospitalisation. An inverse association was identified between a one SD increase in NT-proBNP levels and COVID-19 hospitalisation (OR = 0.59, 95% confidence interval (CI) = [0.38, 0.93], FDR P = 0.046). No associations in relation to long-COVID as a binary outcome had FDR P < 0.05. Full summary statistics are provided in **Supplementary Table 3**.




Figure 2. Disease associations for GDF15 and NT-proBNP in Generation Scotland ($N \ge 16,963$). Fully-adjusted hazard ratios from Cox PH mixed effects regression models between protein levels and incident diseases are plotted with 95% confidence intervals. The six associations in red had FDR P < 0.05 in basic and P < 0.05 in fully-adjusted models, whereas associations that had P > 0.05 are shown in black. Hazard ratios are plotted per 1 SD increase in the rank-base inverse normalised levels of each marker. Fully-adjusted models controlled for age, sex, relatedness and common health and lifestyle factors (smoking, alcohol intake, BMI, social deprivation and years of education).

GDF15 and NT-proBNP epigenetic associations

In variance components analysis of GDF15 and NT-proBNP in Generation Scotland (N \geq 16,963), DNAm explained 36% of the variance in GDF15 levels (lower and upper confidence intervals [CIs] = 32% to 39%) and 32% of the variance in NT-proBNP levels (lower and upper CIs = 27% to 36%). In the EWAS, there were 12 and 4 associations (Bayesian Posterior Inclusion Probability [PIP] > 95%) between differential DNAm at 14 unique CpG sites and the levels of GDF15 and NT-proBNP, respectively. The CpG sites cg03546163 (*FKBP5*) and cg13108341 (*DNAH9*) were associated with

both GDF15 and NT-proBNP. **Table 1** summarises the CpG sites, the biomarkers they associated with, the genes the CpGs are annotated to, and a selection of traits that DNAm at these CpGs have previously been associated with in EWAS studies. The full index of MRC IEU EWAS Catalogue associations (available as of August 2023) for these 14 CpG sites are available in **Supplementary Table 4**.

CpG	PIP	Biomarker	CpG Gene	CpG trait associations (MRC-IEU EWAS Catalogue)
	0.98,	GDF15,		Chronic kidney disease, fetal vs adult liver, body mass index,
cg03546163*	0.96	NT-proBNP	FKBP5	waist circumference, mortality, age, neurodegenerative disorders.
cg13108341*	1.00, 0.98	GDF15, NT-proBNP	DNAH9	Cancer treatment
cg00757033	1.00	NT-proBNP	WDR51B	Crohn's disease, inflammatory bowel disease, age
cg05412028	0.99	NT-proBNP	ABCC4	Age, ageing, primary Sjogrens syndrome
cg19693031	1.00	GDF15	TXNIP	Fetal vs adult liver, triglycerides, sex, hbA1c, alcohol consumption, blood pressures, hepatic fat, waist circumference, cholesterol measures, age.
				Type 2 diabetes, primary Sjogrens syndrome, C-reactive protein, body mass index, serum high-density lipoprotein cholesterol, Crohn's disease, body mass index, coagulation factor VIII,
cg02650017	1.00	GDF15	PHOSPHO1	eosinophilia, age.
cg06918740	1.00	GDF15	N/A	N/A
cg08900409	1.00	GDF15	PGPEP1	Age
cg25460262	1.00	GDF15	GDF15	Fetal vs adult liver
cg21088460	1.00	GDF15	GDF15	N/A
cg05575921	1.00	GDF15	AHRR	Extensive set of smoking-associated traits, lung function/cancer traits, body mass index, serum cotinine, C-reactive protein, IgG glycosylation measures, educational attainment, cognitive ability, statin use, urinary cadmium, mortality, post-traumatic stress disorder, age, acute myocardial infarction.
cg25410121	1.00	GDF15	N/A	N/A
cg15058033	0.97	GDF15	PLXNB2	N/A
cg16993186	0.97	GDF15	CELF2	N/A

Table 1. EWAS of GDF15 and NT-proBNP levels in Generation Scotland (N \geq 16,963). Posterior inclusion probabilities (PIPs) are provided for all CpG-protein associations (PIP > 0.95) in the BayesR EWAS. * Two CpGs were associated with both GDF15 and NT-proBNP. A selection of traits implicated in associations (P<3.8x10⁻⁶, with n>100) with the CpGs from the MRC-IEU EWAS Catalogue (as of August 2023) are shown. HbA1c: glycated haemoglobin. IgG: immunoglobulin G.

EpiScores for GDF15 and NT-proBNP within Generation Scotland

EpiScores for GDF15 and NT-proBNP were initially trained and tested in subsets of Generation Scotland that were unrelated to one another. Predictor weights for EpiScores are available in **Supplementary Table 5**. Performance in the test set was modelled through the incremental variance (R²) in protein levels that scores could explain beyond a null linear regression model that adjusted for age and sex. The EpiScore for GDF15 trained using the full set of EPIC array probes had an R² of 12.2%, whereas the NT-proBNP EpiScore had an R² of 5.7%. Similar performance was observed when comparing with EpiScores trained using sites available on the 450k array subset (**Supplementary Fig. 1**). When modelling EpiScores and polygenic risk scores (PRS) derived for each protein (**see Methods**), additive effects beyond the null model were observed for GDF15 (R² of 15.5%) and NT-proBNP (R² of 6.9%). A full summary of the results is provided in **Supplementary Table 6**.

EpiScore replication of protein biomarker associations within Generation Scotland

The same Cox PH model structure (as shown in **Fig. 2**) was used to directly compare protein levels and EpiScores in the Generation Scotland test. All protein-disease associations – except the association between NT-proBNP and ischaemic stroke – were replicated by EpiScores in fully-adjusted models (**Fig. 3**, **Supplementary Table 7**). Mean time-to-onset, counts for cases and controls and full summary statistics are available in **Supplementary Table 7**. Mean attenuation in the absolute log of the HR due to the additional adjustment for lifestyle factors beyond age and sex was 6% for protein associations and 12% for EpiScore associations. Of the four protein EpiScore associations identified in fully-adjusted models, three withstood further adjustment for estimated immune cell proportions (attenuation in the absolute log of the HR ranging from 0 - 9%). The association between the GDF15 EpiScore and dementia had P = 0.064, with 5% attenuation in the absolute log of the HR. **Supplementary Table 7**). As only five instances of COVID-19

hospitalisation and nine instances of long-COVID were reported in the test population, we did not conduct protein EpiScore and protein comparisons for these outcomes.




Figure 3. Comparison of EpiScores versus measured protein equivalents in fully-adjusted associations with incident diseases in the Generation Scotland test sample ($N \ge 2,808$). For each disease, the protein-disease association is plotted, with the equivalent protein EpiScore-disease association shown directly beneath it for comparison. Hazard ratios are plotted per 1 SD increase in the rank-based inverse normalised levels of each marker. Nine associations (red) had FDR P < 0.05 in basic and P < 0.05 in fully-adjusted Cox proportional hazards mixed effects models in the test samples. Fully-adjusted models adjusted for age, sex, relatedness and common lifestyle risk factors (smoking, alcohol intake, BMI, social deprivation and years of education). Associations that were non-significant (P > 0.05 in fully-adjusted models) are shown in black.

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

EpiScore application to the LBC1936 external cohort EpiScores for each protein were then retrained in the entire Generation Scotland sample (N_{GDF15} = 17,489 and N_{Nt-proBNP} = 16,963). Although we make predictor weights for EpiScores trained on the full EPIC array probes and the subset of probes on the older 450k array available (Supplementary **Table 8**), the LBC1936 external test cohort in this study measured DNAm using the 450k array. Thus, the EpiScores trained on the 450k probe subset were projected into this population for external validation. In the LBC1936 test sample ($N_{GDF15} = 322$ and $N_{Nt-proBNP} = 500$), incremental R^2 values of 8.9% for GDF15 and 8.1% for NT-proBNP EpiScores were observed, beyond age and sex-adjusted linear regression models (Fig. 4a). When a PRS for each protein was modelled together with the EpiScores, incremental variance explained rose to 13.7% and 9.1% for GDF15 and NT-proBNP, respectively (Supplementary Table 9). Finally, the GDF15 EpiScore generated previously by Lu et al as part of the GrimAge biological age acceleration predictor (23) was projected into the Wave 4 GDF15 test set (322 individuals) and evaluated. It explained 5.6% of the variance in GDF15 beyond age and sex, as compared to the 8.9% observed modelling our updated GDF15 score. The two GDF15 EpiScores had a Pearson correlation r = 0.32 in the test sample. EpiScore associations with brain health traits in LBC1936 The EpiScores that were validated against protein measures in the LBC1936 Wave 4 external test set were then projected into methylation measured at Wave 1 (a time point nine years prior), which has a larger DNAm sample available but no protein measures. Structural equation models were then run to characterise associations between the protein EpiScores and five brain health traits (cognitive ability and four structural brain imaging measures). This allowed for EpiScore relationships with both crosssectional brain health (Wave 1, N=895 individuals with EpiScores, total model N=1,091) and

longitudinal change in brain health (Waves 1-5 for cognitive change and Waves 2-5 for brain

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

(Supplementary Table 11).

imaging changes) to be tested (five brain health traits x two EpiScores x cross-sectional and longitudinal associations = 20 hypothesis tests). Seven of the twenty basic model associations tested had FDR P < 0.05 (Supplementary Table 10). All seven associations involved cross-sectional brain health phenotypes and had negative effect estimates (standardised betas ranging from -0.05 to -0.19). Higher GDF15 and NT-proBNP EpiScores were associated with lower general cognitive ability and lower brain volumes. None of the ten slope associations assessing relationships between the EpiScores and longitudinal change in the five brain health phenotypes were significant at FDR P < 0.05. In models that further adjusted for additional health and lifestyle factors, five associations had P < 0.05 (Fig.4b, Supplementary Table 10). A one standard deviation increase in GDF15 EpiScore levels was associated with lower normal appearing white matter volume (Beta = -0.07, SE = 0.02, P = 2.2×10^{-3}), poorer general cognitive ability (Beta = -0.09, SE = 0.04, P = 9.1×10^{-3}) and lower total brain volume (Beta = -0.05, SE = 0.02, $P = 3.5 \times 10^{-3}$). A one standard deviation increase in NT-proBNP EpiScore levels was associated with lower normal appearing white matter volume (Beta = -0.05, SE = 0.02, P = 0.02) and lower total brain volume (Beta = -0.03, SE = 0.01, P = 0.03). In a sensitivity analysis that further adjusted for immune cell proportions, the two NT-proBNP associations were attenuated (P > 0.07) and the associations between NT-proBNP and lower cognitive ability was found to be significant (Beta = -0.10, SE = 0.04, P = 6.0×10^{-3}). In the sensitivity analysis, the three GDF15 associations remained significant (P < 0.05), with a mean attenuation of 11% in Beta effect magnitude (Supplementary **Table 10**). Individuals consented to share disease information from electronic health records from Wave 2 of the study onwards. In Cox regression models that utilised Wave 2 as the baseline and modelled incident dementia as the outcome ($N_{cases} = 108$, $N_{controls} = 672$, mean time-to-event for cases = 8.6 years [SD] 3.42] and maximum follow-up of 14.3 years), no associations were identified for either EpiScore




Figure 4. External assessment of the GDF15 and NT-proBNP EpiScores in LBC1936. a, Correlation plots between measured protein levels and GDF15 (orange) and NT-proBNP (red) EpiScores in the LBC1936 Wave 4 external test set ($N_{GDF}=322,\ N_{NT-proBNP}=500$). Pearson correlation coefficients are annotated in each instance. b, Standardised beta coefficients derived from structural equation models (SEMs) between EpiScore levels at LBC1936 Wave 1 (N=895 with DNAm, N=1,091 total) and cross-sectional measures of brain health traits that had FDR P < 0.05 in basic (age and sex adjusted) models and P < 0.05 after adjustment for further lifestyle covariates. All associations had a negative beta coefficient (blue). Twenty EpiScore-trait associations were tested in total: 10 cross-sectionally and 10 assessing longitudinal change in brain traits.

Discussion

Here, biomarker-disease associations for GDF15 and NT-proBNP were first observed in Generation Scotland, prior to developing EpiScores for these proteins. EpiScores replicated protein associations with incident diseases in the Generation Scotland test sample. In the LBC1936 external test population, the GDF15 and NT-proBNP EpiScores explained 9% and 8% of the variance in the

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

protein levels, respectively, with higher levels of the EpiScores associated with poorer brain health cross-sectionally. EWAS of each protein highlighted 14 CpGs with differential DNAm. This study provides EpiScores for GDF15 and NT-proBNP trained in the largest samples to date as tools for health stratification. Despite the LBC1936 test set being older than the Generation Scotland cohort (mean age of 79 versus 48 years), the EpiScores had R² values comparable to those observed in the Generation Scotland test set. In the external LBC1936 test set, the GDF15 EpiScore had improved performance (an additional R² of 3.3%) when compared to the GDF15 EpiScore derived by Lu et al in 2019 as part of the GrimAge biological age acceleration predictor (23). This is likely due to differences in the sample sizes used for training the two GDF15 scores (2,356 individuals as compared to 17,489 individuals in our study). It may also be due to our training and testing populations having more homogeneous ancestry (Scottish) than the populations used to train the original GrimAge GDF15 score (mixed white European ancestry). No other EpiScores for either GDF15 or NT-proBNP exist in the literature to our knowledge; these EpiScores can therefore be utilised as new tools for risk stratification and can be projected into any cohort with Illumina-based DNAm. We provide EpiScore weights trained on both the 450k and EPIC arrays for use in future research. Generation Scotland is one of the world's largest single cohort resources with DNAm, protein measures, and extant data linkage to electronic health records. This allowed for direct comparisons between protein and EpiScore measures in the context of incident disease analyses, which has only recently been possible owing to the expansion of the cohort's epigenetic resource. As DNAm may record chronic exposure to a range of environmental risk factors (30) and biological processes such as inflammation (20,31), EpiScores may be reflective of a range of biological pathways that occur upstream of disease diagnoses. Given that GDF15 and Nt-pro-BNP are promising biomarkers for a range of diseases, our EpiScores are well-positioned candidates with many potential use-cases. The

results of inclusion of the PRS for proteins in incremental variance models suggested that EpiScore

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

signals were largely independent of genetic architectures on the proteins, as additive improvements in incremental variance observed when PRS and EpiScores were modelled together. This is in concordance with previous studies that found additive epi/genetic heritability estimates for plasma protein levels (32,33). While we have previously regressed out protein quantitative trait loci (pQTLs) from proteins prior to training EpiScores (25), there is an argument that EpiScores capturing a combination of genetic and epigenetic signatures may enhance the disease-predictive signal available. Both approaches are likely viable for the creation of new biomarkers. The higher proportion of variance explained by the GDF15 EpiScore as compared to the NT-proBNP EpiScore suggests that GDF15 was better-characterised by DNAm differences across the genome. This may be due to its association with chronic inflammation, as we have observed particularly strong DNAm signatures associated with inflammatory proteins in previous work (25,34). A stronger DNAm signature was also observed for GDF15 in our EWAS analyses. To our knowledge, this represents the first EWAS of NT-proBNP. The only other EWAS of GDF15 levels was performed by us previously, using GDF15 measures from the SomaLogic assay (34), where we identified no associations for GDF15 passing Bonferroni correction. The improved power to detect associations in the present study (17,489 rather than 774 individuals) may have facilitated identification of associations in the present study. There were two CpG sites associated with both GDF15 and NTproBNP (cg03546163 in FKBP5 and cg13108341 in DNAH9), which suggests a partially-shared DNAm signature across the proteins. FK506-binding protein 5 (FKBP5) is implicated in cellular stress response (35). One previous study found cg03546163 to be differentially methylated in 107 individuals with type 2 diabetes that went onto develop end stage renal disease, versus 253 controls who did not (36). The lack of associations with incident ischaemic heart disease in the Generation Scotland test set may be due to limited sample size, as an association between protein NT-proBNP and ischaemic heart disease was observed in the full Generation Scotland sample. Additionally, the GDF15

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

EpiScore association with incident dementia observed in Generation Scotland did not replicate in LBC1936. This may be due to differences in the way the phenotypes were defined across LBC1936 (consensus committee) versus Generation Scotland (Read and ICD codes only), or different cohort sampling frames and recruitment strategies. Our findings support previous work identifying associations between GDF15 and Nt-proBNP protein levels and severe COVID-19 outcomes in hospitalised individuals (12,13). Although very few hospitalisation cases were available (n=28), both proteins (sampled a mean of 11 years prior to COVID-19 diagnoses) associated with subsequent hospitalisation due to COVID-19. GDF15 is likely to be elevated in individuals with multiple morbidities that may contribute towards greater risk of hospitalisation due to viral illnesses. Diabetes has been associated with increased risk of hospitalisation and adverse outcomes in COVID-19 (37,38). Both proteins (and equivalent EpiScores) should be investigated in populations that have DNAm quantified nearer to, or at COVID-19 diagnoses to further resolve these signals. This study has several limitations. First, whereas it was advantageous to have common ancestry across both (Scottish) training and validation datasets, future studies should test EpiScores across larger populations that include non-European ancestries and larger age ranges as data become available. Second, emerging evidence has quantified differences in genetic associations with the measurements of the same proteins across panels that use antibody-based versus aptamer-based quantification methods (39). A particular example of interest from this study was GDF15 levels, which was highlighted as a protein that may have different conformational shapes (isoforms) that are targeted by the two assay methods (39). While it is likely that increased training sample size led to improved performance of our GDF15 score versus the GrimAge GDF15 score in the LBC1936 test set, it is possible that technical or biological variability across protein assays may also underlie differences in performance of scores. EpiScores trained on protein measurements from different panels should be therefore be compared further when data become available. Similarly, differences

in the protein assay method across the previous EWAS of GDF15 (aptamer-based) that we ran and the present study (immunochemiluminescence) may also introduce variability and EWAS across multiple protein panels should be compared when samples are available.

Conclusions

In conclusion, EpiScores for blood-based GDF15 and NT-proBNP levels are generated in this study and have been found to be useful indictors of disease risk stratification, with disease-specific usecases. The EpiScores can be derived in any population with Illumina-based DNAm measurements and may be integrated into epigenetic screening panels in future to better-identify high-risk individuals.

Methods

Generation Scotland

Generation Scotland is a population-based cohort study that includes ~8,000 families from across Scotland (26,27). Study recruitment of 23,960 participants occurred between 2006 and 2011, while participants were aged between 18 and 99 years. In addition to completing health and lifestyle questionnaires, participants donated blood samples for biomarker and omics measurement. Details on DNAm quality control in Generation Scotland are provided in **Supplementary Information**. The quality-controlled DNAm dataset comprised a total of 18,413 individuals with 760,838 CpG sites available on the EPIC array. GDF15 and NT-proBNP measurement details are provided in **Supplementary Information**. There were 18,413 individuals with GDF15 measures (**Supplementary Table 1**) and these were subset to 17,489 individuals that had DNAm (mean 1038.7 pg/mL [SD 928]). There were 17,863 individuals with NT-proBNP measures, with 16,963 that had DNAm available (mean 94.6 pg/mL [SD 211.2]). Electronic health records via data linkage to GP records (Read 2 codes) and hospital records (10th revision of the International Classification of

Diseases codes [ICD-10 codes]) were assessed prospectively from the time of blood draw. Incident data for all-cause dementia, type 2 diabetes, ischaemic stroke and ischaemic heart disease were considered with censoring date October 2020. Dementia cases were defined as per a previous review of dementia linkage codes (40), whereas code lists for all other diseases are available in **Supplementary Tables 12-14**. Prevalent cases (ascertained via retrospective linkage or self-report from a baseline questionnaire) were excluded from each disease trait, leaving only incident diagnoses. Dementia analyses were limited to cases/controls with age of event/censoring \geq 65 years. Type 1 and juvenile diabetes cases were treated as control observations in the type 2 diabetes analyses. Death was treated as a censoring event.

Lothian Birth Cohort 1936

The Lothian Birth Cohort 1936 (LBC1936) is a longitudinal study of ageing of people residing in Edinburgh and surrounding areas in Scotland (N = 1,091) (28,29). Individuals were born in 1936 and completed an intelligence test when they were 11 years old. They were later recruited to the cohort at a mean age of 70 years old and have been followed up triennially for a series of cognitive, clinical, social and physical measurements in five Waves (mean ages 70, 73, 76, 79 and 82 – all with SD below 1 for measures at each Wave). Blood samples were taken and used to derive protein, epigenetic and genetic measurements. Sample measurement details for the DNAm measures available in LBC1936 are provided in **Supplementary Information**. DNAm is available at the four successive waves of the study (N=895, 787, 619 and 507 in Waves 1, 2, 3 and 4, respectively). Both GDF15 (N=322) and NT-proBNP (N=500) serum levels were measured at Wave 4 of the study (mean age 79 years, SD 0.6) and were used to externally test EpiScore performance. From Wave 2 of the LBC1936, individuals consented for linkage to health records for research. Dementia cases were defined by a consensus committee that completed decisions in August 2022 (41). Potential cases were identified through a combination of electronic health record linkage, death certificate data and clinician visits to individuals that were suspected of having cognitive impairments or dementia. Of

the 865 individuals who had provided linkage consent at Wave 2, 118 were confirmed as having dementia.

Epigenome-wide association studies in Generation Scotland

The xBayesR+ software implements penalised Bayesian regression on complex traits (30). The BayesR method has been found to outperform linear and mixed model approaches and implicitly adjusts for probe correlations, data structure (such as relatedness) and unobserved confounders (30,32). Prior mixture variances for the methylation data (760,838 CpG sites) were set to 0.001, 0.01 and 0.1 and epigenome-wide associations studies (EWAS) were run for GDF15 (N=17,489) and NT-proBNP (N=16,963) levels in Generation Scotland. Protein measurements were transformed by rank-based inverse normalisation, regressed onto age, sex and 20 genetic principal components and scaled to have a mean of 0 and variance of 1. DNAm measurements in beta format were regressed onto age, sex and processing batch and scaled to have a mean of 0 and variance of 1. Houseman immune cell estimates were included as fixed effect covariates (42). Effect size estimates were obtained through Gibbs sampling over the posterior distribution, conditional on input data. The Gibbs protocol had 10,000 samples, with 5,000 samples of burn-in followed by a thinning of 5 samples to reduce autocorrelation. Methylation probes that had a posterior inclusion probability of ≥□95% were deemed to be significant for each protein.

EpiScore development

Elastic net penalised regression was used to train EpiScores for GDF15 and Nt-pro-BNP levels. As Generation Scotland has extensive phenotyping and extant linkage to primary care and hospital records, EpiScores were first trained and tested in subsets of the full sample that were unrelated to one another to facilitate direct comparisons between EpiScore and protein levels in associations with incident diseases. EpiScores were then retrained on the full Generation Scotland sample and tested in LBC1936 – an external cohort. For both analyses, DNAm beta values were considered with missing

CpG measurements mean imputed. To generate alternative versions of the EpiScores that can be applied to existing cohort studies with older Illumina array data (450k array), CpGs were filtered to the intersection of the 450k and EPIC array sites. A total of 760,838 EPIC array probes and 390,461 450k probes were available. CpG measurements were scaled to have a mean of 0 and variance of 1, prior to training. Protein measurements in training samples were transformed by rank-based inverse normalisation, regressed onto age, sex and 20 genetic principal components and scaled to have a mean of 0 and variance of 1. Penalised regression models were performed using Big Lasso (Version 1.5.1) in R (Version 4.0) (43). GDF15 and NT-proBNP protein levels were the outcomes. An elastic net penalty was specified (alpha=0.5). In the within-Generation Scotland analyses 10-fold cross validation was applied to select the lambda value that minimised the mean prediction error, whereas 20-fold cross validation was applied when training EpiScores in the full Generation Scotland sample. A summary of the individuals with protein measurements available that were used to train and test EpiScores in the initial, within-Generation Scotland analyses is provided in **Supplementary Fig. 2**. Briefly, individuals that were part of the same family as disease cases in the test sample were excluded from the training sample. In the test subset of Generation Scotland, control individuals that were related to those in the training sample were excluded. A total of 8,207 individuals with GDF15 and 8,002 individuals with NT-proBNP measurements were therefore used to train EpiScores, while 2,954 individuals with GDF15 and 2,808 individuals with NT-proBNP measurements comprised the test samples. When retraining the EpiScores on the full Generation Scotland sample, there were 17,489 and 16,963 individuals available for the GDF15 and NT-proBNP EpiScores, respectively. **Supplementary Fig. 3** summarises the training and testing samples used, which included 500 individuals with NT-proBNP and 322 individuals with GDF15 measures in the external LBC1936 test set.

EpiScore testing

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

To test EpiScores, the additional variance in protein levels that the EpiScores explained over a null model was quantified by running the following models: Model 1: protein \sim age + sex Model 2: protein ~ age + sex + protein EpiScore The incremental variance (R^2) in protein levels explained due to the protein EpiScore was calculated by subtracting the R^2 derived from model 1 from that in model 2. In these models, scaled, rank-based inverse normalised protein levels were used for testing. Pearson correlation coefficients were also calculated between GDF15 and NT-proBNP levels and their respective EpiScores in the test set and plotted. Protein EpiScores were tested using the described approach in both the Generation Scotland test subset (N≥2,808) and the individuals in Wave 4 of the LBC1936 external cohort that had measures of the proteins available ($N_{GDF} = 322$, $N_{NT-proBNP} = 500$). To assess the incremental variance that could be attributed to genetic architectures of the proteins, polygenic risk scores (PRS) for the proteins were calculated using genome-wide association study (GWAS) summary statistics generated in the Generation Scotland population via BOLT-LMM (44) (see Supplementary Information). A summary of sentinel protein quantitative trait loci (pQTLs) identified by conditional and joint analyses (COJO) via Genome-wide Complex Trait Analysis (GCTA) software (45) for the GWAS results is available in **Supplementary Table 15**. PRS were derived using PRSice software (46). The PRS utilised pQTLs that had $P < 5x10^{-8}$, with clumping (parameters: $R^2 = 0.25$, distance = 250kb, p1 = 1). PRS were modelled in incremental variance assessments singularly and additively with the EpiScores in the test sets in relation to measured proteins. Cox proportional hazards analyses in Generation Scotland Cox proportional hazards mixed effects regression models were used to assess the relationship between measured levels of GDF15 (N=17,489) and NT-proBNP (N=16,693) levels in the baseline

Generation Scotland sample and four incident morbidities. The same model structure was also used

in the test subset of the Generation Scotland sample where proteins and EpiScores were available for direct comparisons. All models were run using coxme (47) (Version 2.2-16) with a kinship matrix accounting for relatedness. Cases included those diagnosed after baseline who had died, in addition to those who received a diagnosis and remained alive. Controls were censored if disease free at time of death, or at the end of the follow-up period. Date of censoring was set to October 2020, which was the latest date of the GP data linkage information. Protein levels were rank-based inverse normalised and scaled to have a mean of 0 and variance of 1 prior to analyses. Basic models were run adjusting for age and sex. Fully-adjusted models further controlled for alcohol consumption (units consumed in the previous week); social deprivation (assessed by the Scottish Index of Multiple Deprivation (48)); body mass index (kilograms/height in metres squared); educational attainment (an 11-category ordinal variable) and a DNAm-based score for smoking status (49). Each of these covariates was sampled at baseline. An FDR multiple testing correction P < 0.05 was applied to basic model associations across all diseases tested. Basic associations were considered to be significant if they had FDR P < 0.05. Associations in fully-adjusted models were considered to be significant if they had unadjusted P < 0.05. Proportional hazards assumptions were checked through Schoenfeld residuals (global test and a test for the protein variable) using the coxph and cox.zph functions from the survival package (50) (Version 3.2-7). For each association failing to meet the assumption (Schoenfeld residuals P < 0.05), a sensitivity analysis was run across yearly follow-up intervals. There were minimal differences in hazard ratios between follow-up periods that did not violate the assumption and those that did. All associations were therefore retained.

COVID-19 analyses in Generation Scotland

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

Associations between measured levels of GDF15 and NT-proBNP and subsequent long-COVID (derived through CovidLife study survey 3 questionnaire (51)) or COVID-19 hospitalisation (derived

through hospital linkage) were tested in the full Generation Scotland population. The preparation of the two binary outcome variables (long-COVID or hospitalisation due to COVID-19) is detailed in **Supplementary Information**. Logistic regression models with either hospitalisation (28 of 491 possible individuals) or long-COVID status (87 of 269 possible individuals) were run, with standardised (measured) proteins as the independent variables. Controls were defined as individuals that had COVID-19 but did not experience hospitalisation or long-COVID. Sex and age at COVID testing were adjusted for in the models. The latter was defined as the age at positive COVID-19 test or 1st January 2021 if COVID-19 test data were not available.

EpiScore associations with brain health traits in LBC1936

As longitudinal cognitive testing and brain morphology measures are available in LBC1936, structural equation models (SEM) were used to examine the relationship between each EpiScore and brain health traits (cross-sectionally and longitudinally). Outcomes included: general cognitive ability (g), total brain volume, normal-appearing white matter volume, global grey matter volume and white matter hyperintensity volume. Cognitive test data were available at all measurement Waves (mean ages 70, 73, 76, 79 and 82) and brain magnetic resonance imaging (MRI) data were available from the second Wave (mean ages 73, 76, 79 and 82). Information on how the SEM analyses were constructed, with information on the number of individuals with cognitive and brain imaging measures at each Wave is included in **Supplementary Information**. Basic models were run with adjustment for age and sex, whereas fully-adjusted models included further covariates: DNAmderived immune cell proportion estimates, DNAm-derived smoking score (49), self-reported alcohol consumption, BMI and the Scottish Index of Multiple Deprivation (52). Intercept (cross-sectional associations) and slope (longitudinal change) coefficients were extracted. A total of 1,091 individuals were modelled as part of the SEM analyses, with 895 individuals that had EpiScore measures available at Wave 1.

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

IgG – Immunoglobulin G

Individuals consented to share disease information from electronic health records from Wave 2 of the study onwards. Cox PH models were run to test associations between Wave 2 GDF15 and NTproBNP EpiScores and incident dementia diagnoses after Wave 2 baseline, with basic adjustments for age and sex. The test population included 780 individuals who had dementia ascertainment and EpiScore information available at Wave 2, with 108 of these individuals having received a dementia diagnosis post-baseline (mean time-to-event 8.6 years [SD 3.4]). For the 108 incident cases, time-toevent was calculated using age at diagnosis. For controls who had died age at death was used for censoring, whereas age at the date of the dementia consensus meeting decision was taken forward for controls that remained alive. List of abbreviations BMI - Body mass index CI – Confidence interval COJO – Conditional and joint analyses COVID-19 - Coronavirus disease 2019 CpG – Cytosine-phosphate-guanine DNAm – DNA methylation EpiScore – Epigenetic score EWAS – Epigenome-wide association study FDR – False discovery rate GCTA – Genome-wide Complex Trait Analysis GDF15 – Plasma growth differentiation factor 15 GWAS – Genome-wide association study HbA1c – Glycated haemoglobin HR - Hazard ratio ICD – International Classification of Diseases codes IHD – Ischaemic heart disease

543 MRI – Magnetic resonance imaging NT-proBNP – $N\square$ terminal pro \square B \square type natriuretic peptide 544 LBC1936 – The Lothian Birth Cohort of 1936 545 OR – odds ratio 546 547 PH – Proportional hazards 548 PIP – Posterior inclusion probability 549 pQTL – Protein quantitative trait loci 550 PRS – Polygenic risk score 551 SD - Standard deviation 552 SE – Standard error 553 SEM – Structural equation model 554 **Declarations** 555 556 Ethics approval and consent to participate 557 All components of Generation Scotland received ethical approval from the NHS Tayside Committee 558 on Medical Research Ethics (REC Reference Number: 05/S1401/89). Generation Scotland has also 559 been granted Research Tissue Bank status by the East of Scotland Research Ethics Service (REC Reference Number: 20-ES-0021), providing generic ethical approval for a wide range of uses within 560 561 medical research. 562 LBC1936 ethical approval was obtained from the Multicentre Research Ethics Committee for 563 Scotland (Wave 1, MREC/01/0/56), the Lothian Research Ethics Committee (Wave 1, 564 LREC/2003/2/29), and the Scotland A Research Ethics Committee (Waves 2-5, 07/MRE00/58). All 565 participants provided written informed consent. 566 **Consent for publication**

567

Not applicable.

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585

586

587

588

589

590

Availability of data and materials The source datasets from the cohorts that were analysed during the current study are not publicly available due to them containing information that could compromise participant consent and confidentiality. Data can be obtained from the data owners. Instructions for accessing Generation Scotland data can be found here: https://www.ed.ac.uk/generation-scotland/for-researchers/access; the 'GS Access Request Form' can be downloaded from this site. Completed request forms must be sent to access@generationscotland.org to be approved by the Generation Scotland Access Committee. According to the terms of consent for Generation Scotland participants, access to data must be reviewed by the Generation Scotland Access Committee. Applications should be made to access@generationscotland.org. LBC1936 data are available on request from the Lothian Birth Cohort Study, University of Edinburgh https://www.ed.ac.uk/lothian-birth-cohorts/data-access-collaboration. All correspondence and material requests should be sent to Riccardo Marioni at riccardo.marioni@ed.ac.uk. All R code used in analyses is provided at: https://github.com/DanniGadd/EpiScores-GDF15-NT-proBNP. Latent Curve Growth Model (LCGM) LBC cognitive code that was adapted for these analyses is also available at: https://www.ed.ac.uk/lothian-birth-cohorts/summary-data-resources. **Competing interests** R.E.M is an advisor to the Epigenetic Clock Development Foundation, and has received consultant fees from Optima partners. A.M.M has previously received speaker's fees from Illumina and Janssen and research grant funding from The Sackler Trust. R.F.H. has received consultant fees from Illumina and Optima partners. D.A.G. has received consultant fees from and is currently employed in

part-time capacity by Optima partners. D.L.M. is currently employed in part-time capacity by

592

593

594

595

596

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

Optima partners. PW reports grant income from Roche Diagnostics in relation to and outside of the submitted work, as well as grant income from AstraZeneca, Boehringer Ingelheim, and Novartis, outside the submitted work and speaker fees from Novo Nordisk, and Raisio outside the submitted work. NS has consulted for Afimmune, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Hanmi Pharmaceuticals, Merck Sharp & Dohme, Novartis, Novo Nordisk, Pfizer, and Sanofi; and received grant support paid to his University from AstraZeneca, Boehringer Ingelheim, Novartis, and Roche Diagnostics outside the submitted work. All other authors declare no competing interest. Funding This research was funded in whole, or in part, by the Wellcome Trust [104036/Z/14/Z, 108890/Z/15/Z, 221890/Z/20/Z, 218493/Z/19/Z]. For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission D.A.G. is supported by funding from the Wellcome Trust 4 year PhD in Translational Neuroscience: training the next generation of basic neuroscientists to embrace clinical research [108890/Z/15/Z], R.F.H is supported through a MRC IEU Short-term Fellowship, E.B. and R.E.M are supported by Alzheimer's Society major project grant AS-PG-19b-010. Hannah Smith is a student on the Translational Neuroscience PhD Programme and is funded by Wellcome grant [218493/Z/19/Z]. Generation Scotland received core support from the Chief Scientist Office of the Scottish Government Health Directorates (CZD/16/6) and the Scottish Funding Council (HR03006). Genotyping and DNAm profiling of the GS samples was carried out by the Genetics Core Laboratory at the Edinburgh Clinical Research Facility, Edinburgh, Scotland and was funded by the Medical Research Council UK and the Wellcome Trust (Wellcome Trust Strategic Award STratifying Resilience and Depression Longitudinally (STRADL; Reference 104036/Z/14/Z). The DNAm data assayed for Generation Scotland was partially funded by a 2018 NARSAD Young

616

617

618

619

620

621

622

623

624

625

626

627

628

629

630

631

632

633

634

635

636

637

638

Investigator Grant from the Brain & Behavior Research Foundation (Ref: 27404; awardee: Dr David M Howard) and by a JMAS SIM fellowship from the Royal College of Physicians of Edinburgh (Awardee: Dr Heather C Whalley). Recruitment to the CovidLife study was facilitated by SHARE the Scottish Health Research Register and Biobank. Roche Diagnostics supported this study through provision of free reagents and a grant for measurement of NT-proBNP and GDF-15 in Generation Scotland. LBC1936 is supported by the Biotechnology and Biological Sciences Research Council, and the Economic and Social Research Council [BB/W008793/1] (which supports S.E.H.), Age UK (Disconnected Mind project), the Milton Damerel Trust, and the University of Edinburgh. S.R.C. is supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (221890/Z/20/Z). Methylation typing was supported by Centre for Cognitive Ageing and Cognitive Epidemiology (Pilot Fund award), Age UK, The Wellcome Trust Institutional Strategic Support Fund, The University of Edinburgh, and The University of Queensland. J.M.W., is funded by the UK Dementia Research Institute Ltd which is funded by the Medical Research Council, Alzheimer's Society and Alzheimer's Research UK Institute (award no. UKDRI – Edin002, DRIEdi17/18, and MRC MC_PC_17113). D.M.K. is supported by a British Heart Foundation Intermediate Basic Science Research Fellowship (FS/IBSRF/23/25161). **Authors' contributions** D.A.G., and R.E.M. were responsible for the conception and design of the study. D.A.G. carried out all data analyses. D.A.G. and R.E.M. drafted the article. O.C., H.S., E.B., Y.C., R.F.H., D.M., C.F.R., and D.L.Mc. contributed to methodology. A.C., R.F., S.W.M., R.M.W., K.L.E., S.E.H., D.P., A.M.M., C.H., T.R., R.M.W., P.W. and N.S. contributed to the data collection and preparation. D.P., A.T., J.C. and S.R.C. collected and processed LBC1936 data. M.E.B., J.M.W., M.D.C.V.H., and

read and approved the manuscript.

Acknowledgements

641

646

- We acknowledge the participants of the Generation Scotland and Lothian Birth Cohort studies for
- their involvement in the data that have made this work possible. The authors thank all LBC1936 and
- 644 Generation Scotland study research team members who have contributed, and continue to contribute,
- 645 to ongoing studies.

References

- Hageman SHJ, McKay AJ, Ueda P, Gunn LH, Jernberg T, Hagström E, et al. Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease: the
- 649 updated SMART2 algorithm. Eur Heart J. 2022 May 7;43(18):1715–27.
- 650 2. SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk prediction algorithms:
- 651 new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021 Jul
- 652 1;42(25):2439-54.
- 653 3. Pence BD. Growth Differentiation Factor-15 in Immunity and Aging. Front Aging, 2022 Feb 9;0:8.
- 4. Wang Z, Yang F, Ma M, Bao Q, Shen J, Ye F, et al. The impact of growth differentiation factor 15 on the
- risk of cardiovascular diseases: two-sample Mendelian randomization study. BMC Cardiovasc Disord.
- 656 2020 Dec 1;20(1):1-7.
- 5. Tanaka T, Basisty N, Fantoni G, Candia J, Moore AZ, Biancotto A, et al. Plasma proteomic biomarker signature of age predicts health and life span. eLife. 2020 Oct 1;9:1–24.
- 659 6. Gadd DA, Hillary RF, Kuncheva Z, Mangelis T, Admanit R, Gagnon J, et al. Blood protein levels predict
- leading incident diseases and mortality in UK Biobank [Internet]. medRxiv; 2023 [cited 2023 May 22]. p.
- 661 2023.05.01.23288879. Available from:
- https://www.medrxiv.org/content/10.1101/2023.05.01.23288879v1
- 563 7. Shrivastava A, Haase T, Zeller T, Schulte C. Biomarkers for Heart Failure Prognosis: Proteins, Genetic Scores and Non-coding RNAs. Front Cardiovasc Med. 2020 Nov 23;7:252.
- 8. Birukov A, Eichelmann F, Kuxhaus O, Polemiti E, Fritsche A, Wirth J, et al. Opposing Associations of NT-
- 666 proBNP With Risks of Diabetes and Diabetes-Related Complications. Diabetes Care. 2020 Dec
- 667 1;43(12):2930-7.
- 9. Noveanu M, Breidthardt T, Potocki M, Reichlin T, Twerenbold R, Uthoff H, et al. Direct comparison of
- serial B-type natriuretic peptide and NT-proBNP levels for prediction of short- and long-term outcome in
- acute decompensated heart failure. Crit Care. 2011 Jan 5;15(1):1–15.

- 671 10. Myhre PL, Vaduganathan M, Claggett B, Packer M, Desai AS, Rouleau JL, et al. B-Type Natriuretic Peptide 672 During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial. J Am Coll Cardiol. 2019 Mar
- 673 26;73(11):1264-72.
- 11. Zile MR, Claggett BL, Prescott MF, McMurray JJV, Packer M, Rouleau JL, et al. Prognostic Implications of
- 675 Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure. J Am Coll Cardiol.
- 676 2016 Dec 6;68(22):2425-36.
- 12. Myhre PL, Prebensen C, Strand H, Røysland R, Jonassen CM, Rangberg A, et al. Growth Differentiation
- Factor 15 Provides Prognostic Information Superior to Established Cardiovascular and Inflammatory
- Biomarkers in Unselected Patients Hospitalized With COVID-19. Circulation. 2020 Dec 12;142(22):2128.
- Gao L, Jiang D, Wen XS, Cheng XC, Sun M, He B, et al. Prognostic value of NT-proBNP in patients with
 severe COVID-19. Respir Res. 2020 Apr 15;21(1):1–7.
- 682 14. McGrath ER, Himali JJ, Levy D, Conner SC, Decarli C, Pase MP, et al. Growth Differentiation Factor 15 and
- NT-proBNP as Blood-Based Markers of Vascular Brain Injury and Dementia. J Am Heart Assoc [Internet].
- 2020 Oct 6 [cited 2021 Nov 24];9(19). Available from: https://pubmed.ncbi.nlm.nih.gov/32921207/
- Walker KA, Chen J, Zhang J, Fornage M, Yang Y, Zhou L, et al. Large-scale plasma proteomic analysis identifies proteins and pathways associated with dementia risk. Nat Aging. 2021 May 14;1(5):473–89.
- 687 16. Gadd DA, Hillary RF, McCartney DL, Zaghlool SB, Stevenson AJ, Nangle C, et al. Epigenetic scores for the circulating proteome as tools for disease prediction. bioRxiv. 2021 Jul 7;8(5):2020.12.01.404681.
- 17. Cheng Y, Gadd DA, Gieger C, Monterrubio-Gómez K, Zhang Y, Berta I, et al. DNA Methylation scores augment 10-year risk prediction of diabetes. medRxiv. 2021 Nov 21;2021.11.19.21266469.
- 18. Chybowska AD, Gadd DA, Cheng Y, Bernabeu E, Campbell A, Walker RM, et al. Augmenting clinical risk
- 692 prediction of cardiovascular disease through protein and epigenetic biomarkers [Internet]. medRxiv;
- 693 2022 [cited 2023 Jan 5]. p. 2022.10.21.22281355. Available from:
- https://www.medrxiv.org/content/10.1101/2022.10.21.22281355v1
- 19. Stevenson AJ, Gadd DA, Hillary RF, Mccartney DL, Campbell A, Walker RM, et al. Creating and validating
- a DNA methylation-based proxy for interleukin-6. [cited 2021 Mar 9]; Available from:
- https://academic.oup.com/biomedgerontology/advance-article/doi/10.1093/gerona/glab046/6141415
- 20. Zaghlool SB, Kühnel B, Elhadad MA, Kader S, Halama A, Thareja G, et al. Epigenetics meets proteomics in
- an epigenome-wide association study with circulating blood plasma protein traits. Nat Commun. 2020
- 700 Dec 1;11(1):15.
- 701 21. Conole ELS, Stevenson AJ, Maniega SM, Harris SE, Green C, Valdés Hernández MDC, et al. DNA
- 702 Methylation and Protein Markers of Chronic Inflammation and Their Associations With Brain and
- 703 Cognitive Aging. Neurology. 2021 Dec 7;97(23):e2340–52.
- 704 22. Stevenson AJ, McCartney DL, Hillary RF, Campbell A, Morris SW, Bermingham ML, et al. Characterisation
- of an inflammation-related epigenetic score and its association with cognitive ability. Clin Epigenetics.
- 706 2020 Jul 27;12:113.
- 23. Lu AT, Quach A, Wilson JG, Reiner AP, Aviv A, Raj K, et al. DNA methylation GrimAge strongly predicts lifespan and healthspan. Aging. 2019 Jan 1;11(2):303–27.

mespan and nearthspan. Aging, 2019 Jan 1,11(2),303-27.

- 709 24. Hillary RF, Stevenson AJ, McCartney DL, Campbell A, Walker RM, Howard DM, et al. Epigenetic clocks
- predict prevalence and incidence of leading causes of death and disease burden. Clin Epigenet.
- 711 2020;12(115).
- 712 25. Gadd DA, Hillary RF, McCartney DL, Zaghlool SB, Stevenson AJ, Cheng Y, et al. Epigenetic scores for the circulating proteome as tools for disease prediction. eLife. 2022 Jan 1;11.
- 714 26. Smith BH, Campbell A, Linksted P, Fitzpatrick B, Jackson C, Kerr SM, et al. Cohort profile: Generation
- scotland: Scottish family health study (GS: SFHS). The study, its participants and their potential for
- genetic research on health and illness. Int J Epidemiol. 2013;42(3):689–700.
- 717 27. Smith BH, Campbell H, Blackwood D, Connell J, Connor M, Deary IJ, et al. Generation Scotland: The
- 718 Scottish Family Health Study; a new resource for researching genes and heritability. BMC Med Genet.
- 719 2006;7:74.
- 720 28. Taylor AM, Pattie A, Deary IJ. Cohort profile update: The Lothian birth cohorts of 1921 and 1936. Int J 721 Epidemiol. 2018;47(4):1042r.
- 29. Deary IJ, Gow AJ, Pattie A, Starr JM. Cohort profile: The lothian birth cohorts of 1921 and 1936. Int J Epidemiol. 2012;41(6):1576–84.
- 724 30. Trejo Banos D, McCartney DL, Patxot M, Anchieri L, Battram T, Christiansen C, et al. Bayesian 725 reassessment of the epigenetic architecture of complex traits. Nat Commun. 2020;11.
- 726 31. Gadd DA, Hillary RF, McCartney DL, Shi L, Stolicyn A, Robertson N, et al. Integrated methylome and
- phenome study of the circulating proteome reveals markers pertinent to brain health. Zenodo
- 728 [Internet]. 2022 Jul 6 [cited 2022 Jul 6]; Available from: https://zenodo.org/record/6801458
- 729 32. Hillary RF, Trejo-Banos D, Kousathanas A, McCartney DL, Harris SE, Stevenson AJ, et al. Multi-method
- 730 genome- And epigenome-wide studies of inflammatory protein levels in healthy older adults. Genome
- 731 Med. 2020 Jul 8;12:60.
- 732 33. Hillary RF, McCartney DL, Harris SE, Stevenson AJ, Seeboth A, Zhang Q, et al. Genome and epigenome
- wide studies of neurological protein biomarkers in the Lothian Birth Cohort 1936. Nat Commun. 2019
- 734 Dec 1;10(1):3160.
- 735 34. Gadd DA, Hillary RF, McCartney DL, Shi L, Stolicyn A, Robertson NA, et al. Integrated methylome and
- 736 phenome study of the circulating proteome reveals markers pertinent to brain health. Nat Commun.
- 737 2022 Aug 9;13(1):4670.
- 35. Zannas AS, Wiechmann T, Gassen NC, Binder EB. Gene–Stress–Epigenetic Regulation of FKBP5: Clinical and Translational Implications. Neuropsychopharmacology. 2016 Jan;41(1):261–74.
- 740 36. Smyth LJ, Kilner J, Nair V, Liu H, Brennan E, Kerr K, et al. Assessment of differentially methylated loci in
- individuals with end-stage kidney disease attributed to diabetic kidney disease: an exploratory study.
- 742 Clin Epigenetics. 2021 May 1;13(1):99.
- 743 37. Rawshani A, Kjölhede EA, Rawshani A, Sattar N, Eeg-Olofsson K, Adiels M, et al. Severe COVID-19 in
- 744 people with type 1 and type 2 diabetes in Sweden: A nationwide retrospective cohort study. Lancet Reg
- 745 Health Eur [Internet]. 2021 May 1 [cited 2023 Aug 20];4. Available from:
- 746 https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(21)00082-X/fulltext

- 38. Ortega E, Corcoy R, Gratacòs M, Claramunt FXC, Mata-Cases M, Puig-Treserra R, et al. Risk factors for
- severe outcomes in people with diabetes hospitalised for COVID-19: a cross-sectional database study.
- 749 BMJ Open. 2021 Jul 1;11(7):e051237.
- 750 39. Pietzner M, Wheeler E, Carrasco-Zanini J, Kerrison ND, Oerton E, Koprulu M, et al. Synergistic insights
- 751 into human health from aptamer- and antibody-based proteomic profiling. Nat Commun 2021 121. 2021
- 752 Nov 24;12(1):1–13.
- 40. Wilkinson T, Schnier C, Bush K, Rannikmäe K, Henshall DE, Lerpiniere C, et al. Identifying dementia
- outcomes in UK Biobank: a validation study of primary care, hospital admissions and mortality data. Eur
- 755 J Epidemiol. 2019 Jun 15;34(6):557–65.
- 756 41. Mullin DS, Stirland LE, Buchanan E, Convery CA, Cox SR, Deary IJ, et al. Identifying dementia using
- 757 medical data linkage in a longitudinal cohort study: Lothian Birth Cohort 1936. BMC Psychiatry. 2023
- 758 May 1;23:303.
- 759 42. Houseman EA, Accomando WP, Koestler DC, Christensen BC, Marsit CJ, Nelson HH, et al. DNA
- methylation arrays as surrogate measures of cell mixture distribution. BMC Bioinformatics. 2012;13:86.
- 761 43. R. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical
- 762 Computing, Vienna, Austria. URL https://www.R-project.org/. Accessed April 2021. 2020.
- 44. Loh PR, Kichaev G, Gazal S, Schoech AP, Price AL. Mixed model association for biobank-scale data sets.
- 764 Nat Genet. 2018 Jul;50(7):906-8.
- 765 45. Yang J, Ferreira T, Morris AP, Medland SE, Madden PAF, Heath AC, et al. Conditional and joint multiple-
- 766 SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits. Nat
- 767 Genet. 2012 Apr;44(4):369-75.
- 768 46. Euesden J, Lewis CM, O'Reilly PF. PRSice: Polygenic Risk Score software. Bioinformatics. 2015 May
- 769 1;31(9):1466-8.
- 770 47. Therneau TM. coxme: Mixed Effects Cox Models. R package version 2.2-16. https://CRAN.R-
- project.org/package=coxme. Accessed April 2021. 2020;
- 48. GovScot. Scottish Government. The Scottish Index of Multiple Deprivation (SIMD); 1-20. (2016).
- Available from: http://www.gov.scot/ Resource/0050/00504809.pdf. Accessed April 2021. 2016.
- 49. Bollepalli S, Korhonen T, Kaprio J, Anders S, Ollikainen M. EpiSmokEr: A robust classifier to determine
- 775 smoking status from DNA methylation data. Epigenomics. 2019;11(13):1469–86.
- 776 50. Therneau TM. A Package for Survival Analysis in R. R package version 3.2-7, https://CRAN.R-
- project.org/package=survival. Accessed April 2021. 2020;
- 778 51. Fawns-Ritchie C, Altschul DM, Campbell A, Huggins C, Nangle C, Dawson R, et al. CovidLife: a resource to
- 779 understand mental health, well-being and behaviour during the COVID-19 pandemic in the UK.
- 780 Wellcome Open Res 2021 6176. 2021 Jul 7;6:176.
- 781 52. GovScot Scottish Government. Scottish Index of Multiple Deprivation 2006: Technical Report. Available
- 782 at: https://www.gov.scot/publications/scottish-index-multiple-deprivation-2006-technical-report/.
- 783 Accessed August 2023.